Hongjitang

Hongjitang

Crafting Health Across Generations with a Comprehensive Range of Pediatric, Gynecological, Respiratory, Cardiovascular, and Neurological Solutions

Founded 1907 1001-5000 employees Post-IPO Equity Total: $313.00M Manufacturing, Pharmaceutical

Hongjitang is a pharmaceutical company that has been specializing in producing a diverse range of medications including pediatric medicine, gynecological and respiratory drugs, and neuro cancer therapies since 1907. The company offers an extensive product line comprising various forms such as pills, powders, tablets, and capsules. The most recent investment in the company amounted to CNY260.00M and was made on 24 March 2017. The investors involved in this post-IPO equity investment included Qiaojing Capital, Orient Securities, Juqing Ziben, ZhongbingGuangfa Touzi, and Xiamen ChuangshiRenhe Ziben Guanli Youxian Gongsi. Hongjitang's slogan emphasizes the company's commitment to crafting health across generations with a comprehensive range of pediatric, gynecological, respiratory, cardiovascular, and neurological solutions. This positioning aligns with the company's focus on offering pharmaceutical solutions for a wide range of medical needs within these specific areas.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	CNY260.00M	5	Qiaojing Capital, Orient Securities +3	24 Mar 2017
Venture Round	CNY50.00M	5	Qiaojing Capital, Greenwoods Asset Management +3	27 Jul 2015
Angel Round	CNY3.00M	-		28 Oct 2003

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

CNY260.00M

Qiaojing Capital, Orient Securities +3

24 Mar 2017

Venture Round

CNY50.00M

Qiaojing Capital, Greenwoods Asset Management +3

27 Jul 2015

Angel Round

CNY3.00M

28 Oct 2003

FAQ About Hongjitang

Crafting Health Across Generations with a Comprehensive Range of Pediatric, Gynecological, Respiratory, Cardiovascular, and Neurological Solutions

Hongjitang was founded in 1907.

Hongjitang operates in Manufacturing and Pharmaceutical. Its work centres on pharmaceuticals, pediatric medicine, gynecological drugs and respiratory drugs.

Hongjitang has approximately 1001-5000 employees.

Hongjitang has completed 3 funding rounds, raising a total of $313.00M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Hongjitang include 贵州三力制药股份有限公司, Weser Pharma, Sakura Italia, Human Bio Organics Pvt Ltd, Vibcare Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Hongjitang and 贵州三力制药股份有限公司 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Hongjitang

Funding Rounds & Investors (3)

Hongjitang Alternatives & Competitors

FAQ About Hongjitang